A new report highlights the potential pitfalls of formulary exclusion lists used by pharmacy benefit managers.
Daratumumab combination therapy tripled the minimal residual disease negativity rate among patients with multiple myeloma.
The Maraba virus was observed to kill latently infected HIV cells.
Top news of the day from across the health care landscape.
The Centers for Medicare and Medicaid Services finalized a ruling that slashes reimbursement rates on drugs that qualify under the 340B program.
Oral regimen of ledipasvir and sofosbuvir for hepatitis C virus shows improved treatment outcomes.
With new specialty pharmacies emerging and existing pharmacies evolving, accreditation has become more important.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2017
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.